← Back to Clinical Trials
Recruiting NCT04866888

NCT04866888 Placenta Accreta Spectrum Outcome After Uterine Conservation

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT04866888
Status Recruiting
Phase
Sponsor Alexandria University
Condition Placenta Accreta Spectrum
Study Type INTERVENTIONAL
Enrollment 120 participants
Start Date 2021-04-28
Primary Completion 2025-12-01

Eligibility & Interventions

Sex Female only
Min Age 20 Years
Max Age 40 Years
Study Type INTERVENTIONAL
Interventions
closure of the uterine wall defectultrasoundoutpatient hysteroscopy

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 120 participants in total. It began in 2021-04-28 with a primary completion date of 2025-12-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

study will be carried out on patients with placenta accreta spectrum having done uterine conservation and recording immediate outcome of conservation regarding success of the procedure, amount of blood loss and amount of blood transfused and followed up to check the return of menses, any uterine abnormalities by ultrasound or hysteroscopy especially isthmocele and intrauterine synechia.

Eligibility Criteria

Inclusion Criteria: * • Diagnosed sonographically to have placenta accreta spectrum. * Pregnancy is singleton and fetus is alive. * Elective caesarean section done from 35 gestational weeks. Exclusion Criteria: * • Patients requesting hysterectomy. * Coexisting uterine pathology such as fibroids or gynaecological malignancies. * Patients with bleeding diathesis. * Morbid obesity of BMI \>40. * Patients having labour pains or vaginal bleeding before scheduled intervention.

Contact & Investigator

Central Contact

Omar Y Elshorbagy, As.lec

✉ o_kamal13@alexmed.edu.eg

📞 01111362322

Principal Investigator

Mervat S Al-sedik, MD

STUDY CHAIR

faculty of medicine department of obstetrics and gyneacology

Frequently Asked Questions

Who can join the NCT04866888 clinical trial?

This trial is open to female participants only, aged 20 Years or older, up to 40 Years, studying Placenta Accreta Spectrum. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT04866888 currently recruiting?

Yes, NCT04866888 is actively recruiting participants. Contact the research team at o_kamal13@alexmed.edu.eg for enrollment information.

Where is the NCT04866888 trial being conducted?

This trial is being conducted at Alexandria, Egypt.

Who is sponsoring the NCT04866888 clinical trial?

NCT04866888 is sponsored by Alexandria University. The principal investigator is Mervat S Al-sedik, MD at faculty of medicine department of obstetrics and gyneacology. The trial plans to enroll 120 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology